Company intelligence

Vaderis Therapeutics

Biotech

Suggest a correction

Recent changes

Aug 11, 2026Aug 11, 2026Raised $152.5M Series B PR Newswire
Aug 11, 2026Aug 11, 2026New investor: Goldman Sachs Alternatives PR Newswire

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Aug 11, 2026	Series B	$152.5M	—	Goldman Sachs Alternatives outlined = lead	Pulse story

Investors

Goldman Sachs Alternatives

Latest Pulse

Aug 11, 2026Vaderis Raises $152M Series B for Rare Disease TrialVaderis Therapeutics closed an oversubscribed $152.5 million Series B co-led by Goldman Sachs Alternatives and TCGX to fund a global Phase 3 trial of its drug for a rare blood vessel disorder.→

Coverage Timeline

newest first

Aug 11, 2026FUNDINGVaderis Raises $152M Series B for Rare Disease Trial$152.5M Series B→

All Coverage

FUNDING· Aug 11, 2026

Vaderis Raises $152M Series B for Rare Disease Trial

Illustration for: Vaderis Raises $152M Series B for Rare Disease Trial

FUNDING$152.5M Series B

Vaderis Raises $152M Series B for Rare Disease Trial

Vaderis Therapeutics closed an oversubscribed $152.5 million Series B co-led by Goldman Sachs Alternatives and TCGX to fund a global Phase 3 trial of its drug for a rare blood vessel disorder.

Aug 11, 2026DEEP DIVE

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

PR Newswireprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction